GLP-1 Receptor Agonists, or glucagon-like peptide-1 receptor agonists, constitute a class of injectable medications used to manage Type 2 diabetes. Notable drugs in this class include Exenatide and Liraglutide. 

Drug Family and Names: 

• Exenatide: An injectable GLP-1 Receptor Agonist. 
• Liraglutide: Another medication belonging to the GLP-1 Receptor Agonist class for diabetes management. 

Mechanism of Action: 

GLP-1 Receptor Agonists mimic the action of incretin hormones, stimulating insulin release from the pancreas, reducing glucagon production, slowing gastric emptying, and promoting satiety, which collectively help lower blood sugar levels. 

Indications: 

Exenatide and Liraglutide are prescribed: 

• To improve blood sugar control in individuals with Type 2 diabetes. 
• Often used as adjunct therapy with other diabetes medications or as monotherapy. 

Side Effects: 

Common side effects of GLP-1 Receptor Agonists include: 

• Nausea or vomiting 
• Diarrhea 
• Injection site reactions 

Dosage: 

Dosage and frequency may vary, typically administered via subcutaneous injection once daily or weekly, depending on the specific medication and patient’s needs. 

Route of Administration: 

GLP-1 Receptor Agonists, such as Exenatide and Liraglutide, are administered through subcutaneous injections, usually in the abdomen, thigh, or upper arm. 

Precautions and Considerations: 

• These medications may cause gastrointestinal disturbances, especially at the initiation of therapy, which tends to improve over time. 
• They may also lead to weight loss in some individuals. 

Exenatide and Liraglutide, offer a unique approach to managing Type 2 diabetes by mimicking incretin hormone actions, promoting insulin release, and reducing blood sugar levels. They are favored for their dual benefits of improving blood sugar control and potential weight loss.